(DRSK) Aptus Defined Risk - Overview
Etf: Corporate Bonds, U.S. Stocks
Dividends
| Dividend Yield | 3.68% |
| Yield on Cost 5y | 4.09% |
| Yield CAGR 5y | 8.25% |
| Payout Consistency | 89.8% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 7.99% |
| Relative Tail Risk | -5.54% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.10 |
| Alpha | -1.11 |
| Character TTM | |
|---|---|
| Beta | 0.165 |
| Beta Downside | 0.047 |
| Drawdowns 3y | |
|---|---|
| Max DD | 11.33% |
| CAGR/Max DD | 0.57 |
Description: DRSK Aptus Defined Risk January 16, 2026
The Aptus Defined Risk ETF (BATS:DRSK) is an actively managed fund that blends a fixed-income core with a risk-controlled equity overlay. Roughly 75-95 % of the portfolio is allocated to investment-grade corporate bonds, while the remaining capital is used to take long positions in U.S. equities with mechanisms that limit downside risk.
Key quantitative characteristics (as of the latest filing) include an expense ratio of approximately 0.45 %, a weighted-average credit rating of A-, and a portfolio duration of about 5.5 years. The fund’s equity side typically holds a diversified basket of large-cap stocks, resulting in a beta near 0.6 relative to the S&P 500, which helps temper volatility.
Primary macro drivers for DRSK’s performance are the U.S. interest-rate trajectory and corporate credit spread dynamics. A flattening yield curve or a modest rise in rates tends to compress bond yields, while tightening spreads in the investment-grade sector can boost total return. Simultaneously, equity market volatility (VIX) influences the effectiveness of the downside-risk buffer built into the equity component.
For a deeper dive into the fund’s risk-adjusted performance metrics, you might find ValueRay’s analytical platform useful.
What is the price of DRSK shares?
Over the past week, the price has changed by -0.88%, over one month by -2.26%, over three months by -2.17% and over the past year by +4.63%.
Is DRSK a buy, sell or hold?
What are the forecasts/targets for the DRSK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 29.6 | 5.1% |
DRSK Fundamental Data Overview February 04, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 1.45b USD (1.45b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 1.45b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 1.45b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.52% (E(1.45b)/V(1.45b) * Re(6.52%) + (debt-free company))
Discount Rate = 6.52% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)